Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Insights
  3. Events
  4. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Life Sciences
  • Healthcare
Life Sciences

Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.

Learn More
Life Sciences
Healthcare

Accelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.

Learn More
Healthcare
MAIN/Insights
Insights/
U.S. PROGRESS POINT

A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.

LEARN MORE
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS

PODCASTS

"Discover the future through our enlightening podcasts available in the United States.

EXPLORE PODCASTS

FACT SHEET

"IQVIA AI Medical Record Review

LEARN MORE

BLOG

"Decoding DSCSA: Ensuring Compliance in the Pharmaceutical Supply Chain

READ MORE
MAIN/Events
Events/
ON-DEMAND WEBINARS

Visit our library of on-demand webinars.

WATCH ON-DEMAND WEBINARS
UPCOMING EVENTS & WEBINARS

View our upcoming events and webinars.

DISCOVER EVENTS & WEBINARS

EVENT

"26th Controlled Substances and State Regulatory Conference

REGISTER NOW
MAIN/Contact Us
Contact Us/
Fact Sheet
Unintended Consequences: How the Affordable Care Act Helped Grow the 340B Program
Sep 04, 2024
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

Review the summary of IQVIA's study of the 340B Drug Discount Program examining the program's scale by comparing the number of 340B patients and the revenue from 340B drug discounts to the number of vulnerable individuals. In 2021, 25.9% of healthcare users were 340B patients, with 2.1 to 3.6 times more 340B patients than vulnerable individuals, depending on Medicaid inclusion. This ratio increased for patients using certain Medicare-negotiated drugs. From 2013 to 2021, while the vulnerable population nearly halved, 340B revenue grew by 374%, partly due to the Affordable Care Act, leading to a misalignment between 340B revenue and the size of the vulnerable population.

For the full analysis, please read our white paper here.

Related solutions

Contact Us